Related Experiment Video
Updated: May 6, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
[Acute and chronic heart failure in light of the new ESC guidelines]
1Klinik für Innere Medizin III, Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland, janine.poess@uks.eu.
Insights
New European heart failure guidelines recommend mineralocorticoid receptor antagonists for chronic heart failure and ivabradine for specific patient groups. The RELAX-AHF trial shows promise for serelaxin in acute heart failure treatment.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Context:
- The European Society of Cardiology updated its heart failure treatment guidelines in June 2012.
- Existing treatments for chronic and acute heart failure are being re-evaluated based on recent clinical trial data.
Purpose:
- To summarize key innovations in the 2012 European Society of Cardiology guidelines for heart failure.
- To review the pivotal clinical trials informing these new treatment recommendations.
Summary:
- Mineralocorticoid receptor antagonists are now indicated for all stages of symptomatic chronic heart failure (EMPHASIS-HF trial).
- Ivabradine is recommended for heart failure patients (NYHA II-IV, ejection fraction <35%, heart rate >70/min) on beta-blockers (SHIFT trial).
- Cardiac resynchronization therapy (CRT) indications are expanded (RAFT trial), and serelaxin shows promise for acute heart failure (RELAX-AHF trial).
Impact:
- These guideline updates provide clinicians with evidence-based strategies for optimizing heart failure management.
- The integration of new trial data aims to improve patient outcomes in both chronic and acute heart failure settings.
Abstract:
In June 2012, the New Guidelines for the Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology were published. According to the EMPHASIS-HF trial, mineralocorticoid receptor antagonists are indicated in all stages of symptomatic chronic heart failure under treatment with β-blockers and ACE inhibitors. Based on the SHIFT trial, patients with class NYHA II-IV heart failure, an ejection fraction <35%, and sinus rhythm with a heart rate of >70/min despite pharmacological treatment including β-blockers at the maximum tolerated dose should be treated with ivabradin. The RAFT trial justified the extended indication for CRT systems. In acute heart failure, the RELAX-AHF trial showed promising results with serelaxin. This manuscript summarizes the innovations of the new guidelines and the underlying clinical trials.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure III: Clinical Manifestations
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology